ReviewiScience2022
Engineering autonomous closed-loop designer cells for disease therapy.
Review in iScience, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Re-engineering insulin for oral delivery: structural modifications, advanced formulation strategies, and future directions.Drug delivery · 2026Review
- Programmable nanobody circuits for cell selection.bioRxiv : the preprint server for biology · 2026Article
- Nitroglycerin-responsive gene switch for the on-demand production of therapeutic proteins.Nature biomedical engineering · 2025Article
- Designer mammalian living materials through genetic engineering.Bioactive materials · 2025Review
- Genetically engineered macrophages derived from iPSCs for self-regulating delivery of anti-inflammatory biologic drugs.Journal of tissue engineering and regenerative medicine · 2024Article
- Engineering receptors in the secretory pathway for orthogonal signalling control.Nature communications · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Synthetic biology has made it possible to engineer mammalian cells for on-demand delivery of therapeutic agents, providing therapeutic solutions for chronic or intractable diseases. Currently, most of the engineered therapeutic cells are regulated by the administration of exogenous inducers, but the need for repeated administration of these xenobiotics is problematic from the viewpoints of patients' compliance and quality of life, as well as possible side effects. Recently, synthetic biologists started to address these issues by constructing autonomous, closed-loop therapeutic cells, often referred to as designer cells. These cells are equipped with sensing modules that detect and link marker(s) of the target disease to signaling cascades that stimulate the secretion of specified therapeutic agents in a timely and quantitative manner, without the need of exogenous inducers. Here, we review recent work on designer cell engineering and their
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.